Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 290-100 Innovation Drive WINNIPEG MB R3T 6G2 |
Tel: | 1-204-4531301 |
Website: | https://kanebiotech.com |
IR: | See website |
Key People | ||
Philip Renaud Chairman of the Board | Marc Edwards President, Chief Executive Officer, Director | Raymond David Eugene Dupuis Chief Financial Officer |
Lori Christofalos Vice President - Quality & Compliance | Wendy Nachtigall Director of Marketing | Dena Mehraban General Manager of STEM Animal Health |
Business Overview |
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health. |
Financial Overview |
For the fiscal year ended 31 December 2023, Kane Biotech Inc revenues decreased 94% to C$149K. Net loss before extraordinary items increased 17% to C$4.6M. Revenues reflect All Other Segments decrease of 5% to C$149K, International segment decrease of 91% to C$139K, Domestic segment decrease of 99% to C$10K. Higher net loss reflects Fair value adjustment - government loans decrease of 99% to C$4K (income). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $25.64M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.15M as of Dec 31, 2023 |
EBITDA (TTM): | -$3.12M as of Dec 31, 2023 |
Net annual income (TTM): | -$4.56M as of Dec 31, 2023 |
Free cash flow (TTM): | -$2.13M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $8.50M as of Dec 31, 2023 |
Shares outstanding: | 131,844,567 as of Feb 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |